The European Medical Device Ecosystem: Interactions Between Regulation, Innovation, Market Access, and Healthcare Systems.
Abstract
The European Union medical device sector is analysed in several largely separate strands of the literature: regulatory studies of the Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR), innovation research on individual technology classes, commercial market reporting, and health-policy work on adoption and reimbursement. Integration across these dimensions is limited, so the mechanisms by which regulatory change propagates into innovation, market access and healthcare-system outcomes remain poorly specified. This review addresses that gap by proposing and applying a five-stage conceptual framework: Regulation, Evidence, Innovation, Market Access, and Healthcare-System Impact, and by using it to structure a reproducible literature synthesis. Four bibliographic databases and a defined set of institutional sources were searched for the period January 2017 to June 2026, with a targeted update to October 2026 and the geographical scope restricted to the EU-27 and the European Economic Area (EEA); identified records were screened against explicit criteria, and the retained documents were coded against the five framework dimensions. Search, screening and coding records are reported in full, with the PRISMA flow diagram, checklist, screening log and coded corpus provided. Rather than reporting market values as isolated figures, the synthesis examines relationships between certification duration, evidence intensity, segment growth, market concentration and access conditions. Three findings emerge. First, at the segment level, the association between evidence intensity and growth runs in the opposite direction to the one usually assumed: the segments with the heaviest evidence burden, Class III implantable and Class C/D in vitro diagnostics, grow in the mid-single digits, whereas the fastest-growing segments, digital health and wearables, sit predominantly in lower conformity-assessment classes. Certification duration is nevertheless substantial throughout, with median application-to-certificate totals reported at approximately 17-19 months for in vitro diagnostics and 19-22 months for medical devices, so that evidence requirements act less as a uniform brake on growth than as a selection mechanism determining which firms can participate in the most regulated segments. Second, the innovation consequence of regulatory delay has moved from assertion to estimation: a two-market economic model estimates that introducing a three-year supplementary protection certificate limited to Class III devices would raise EU-directed development effort by 13.46% in a single-market EU calibration, and by 5.6% in the two-market setting and manufacturer survey evidence records a reallocation of first approvals and launches away from the EU. Third, the December 2025 targeted revision of the medical device regulation (MDR) and in vitro diagnostic regulation (IVDR), implementing regulation (EU) 2026/977 setting maximum conformity-assessment timelines, the selection of the first two medical devices for joint clinical assessment in October 2026, and the phased mandatory use of the European database on medical devices (EUDAMED) together constitute a partial correction whose effects are not yet observable. The framework identifies where regulatory change translates into consequences for manufacturers, providers and patients, and shows that the chain is well evidenced at its regulatory origin and weakest at its healthcare-system terminus.